Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $436.4 million.

  • Syndax Pharmaceuticals' Total Liabilities rose 63487.6% to $436.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $436.4 million, marking a year-over-year increase of 63487.6%. This contributed to the annual value of $436.7 million for FY2024, which is 64414.15% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Total Liabilities stood at $436.4 million, which was up 63487.6% from $438.7 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Total Liabilities registered a high of $438.7 million during Q2 2025, and its lowest value of $21.6 million during Q3 2022.
  • Moreover, its 5-year median value for Total Liabilities was $47.7 million (2022), whereas its average is $124.7 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Total Liabilities crashed by 4898.37% in 2023, and later skyrocketed by 92965.34% in 2025.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Total Liabilities stood at $41.3 million in 2021, then decreased by 27.86% to $29.8 million in 2022, then soared by 97.01% to $58.7 million in 2023, then soared by 644.14% to $436.7 million in 2024, then dropped by 0.08% to $436.4 million in 2025.
  • Its Total Liabilities was $436.4 million in Q3 2025, compared to $438.7 million in Q2 2025 and $425.6 million in Q1 2025.